KLRS
Kalaris Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.91
−4.50%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-76.7%
Return on equity
-44.5%
Return on assets
-80.9%
Return on invested capital
0.00x
Asset turnover
-$45.4M
Cash from operations
$3.93
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026